RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000017.xml
Exp Clin Endocrinol Diabetes 2023; 131(07/08): 394-401
DOI: 10.1055/a-2066-2696
DOI: 10.1055/a-2066-2696
Review
Primary Aldosteronism Prevalence – An Unfolding Story
Abstract
Primary aldosteronism (PA) is characterized by dysregulated, renin-independent aldosterone excess. Long perceived as rare, PA has emerged as one of the most common causes of secondary hypertension. Failure to recognize and treat PA results in cardiovascular and renal complications, through processes mediated by both direct target tissue insults and indirectly, by hypertension. PA spans a continuum of dysregulated aldosterone secretion, which is typically recognized in late stages after treatment-resistant hypertension and cardiovascular and/or renal complications develop. Determining the precise disease burden remains challenging due to heterogeneity in testing, arbitrary thresholds, and populations studied. This review summarizes the reports on PA prevalence among the general population and in specific high-risk subgroups, highlighting the impact of rigid versus permissive criteria on PA prevalence perception.
Publikationsverlauf
Eingereicht: 30. Januar 2023
Eingereicht: 09. März 2023
Angenommen: 27. März 2023
Accepted Manuscript online:
30. März 2023
Artikel online veröffentlicht:
31. Mai 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Wannachalee T, Lieberman L, Turcu AF. High prevalence of autonomous aldosterone production in hypertension: How to identify and treat it. Curr Hypertens Rep 2022; 24: 123-132 DOI: 10.1007/s11906-022-01176-7.
- 2 Monticone S, D’Ascenzo F, Moretti C. et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018; 6: 41-50 DOI: 10.1016/S2213-8587(17)30319-4.
- 3 Hundemer GL, Curhan GC, Yozamp N. et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: A retrospective cohort study. Lancet Diabetes Endocrinol 2018; 6: 51-59 DOI: 10.1016/S2213-8587(17)30367-4.
- 4 Mulatero P, Monticone S, Bertello C. et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab 2013; 98: 4826-4833 DOI: 10.1210/jc.2013-2805.
- 5 Salcuni AS, Carnevale V, Battista C. et al. Primary aldosteronism as a cause of secondary osteoporosis. Eur J Endocrinol 2017; 177: 431-437 DOI: 10.1530/EJE-17-0417.
- 6 Reincke M, Rump LC, Quinkler M. et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab 2009; 94: 869-875 DOI: 10.1210/jc.2008-1851.
- 7 Sechi LA, Novello M, Lapenna R. et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295: 2638-2645 DOI: 10.1001/jama.295.22.2638.
- 8 Wu V-C, Wang S-M, Huang K-H. et al. Long-term mortality and cardiovascular events in patients with unilateral primary aldosteronism after targeted treatments. Eur J Endocrinol 2021; 186: 195-205 DOI: 10.1530/EJE-21-0836.
- 9 Rossi GP, Maiolino G, Flego A. et al. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term. Hypertension 2018; 71: 585-591 DOI: 10.1161/HYPERTENSIONAHA.117.10596.
- 10 Chen Y-Y, Lin Y-HH, Huang W-C. et al. Adrenalectomy improves the long-term risk of end-stage renal disease and mortality of primary aldosteronism. J Endocr Soc 2019; 3: 1110-1126 DOI: 10.1210/js.2019-00019.
- 11 Hundemer GL, Curhan GC, Yozamp N. et al. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension 2018; 72: 658-666 DOI: 10.1161/HYPERTENSIONAHA.118.11568.
- 12 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916 DOI: 10.1210/jc.2015-4061.
- 13 Huang W-C, Lin Y-H, Wu V-C. et al. Who should be screened for primary aldosteronism? A comprehensive review of current evidence. J Clin Hypertens (Greenwich) 2022; 24: 1194-1203 DOI: 10.1111/jch.14558.
- 14 Zekarias K, Tessier KM. Screening rate for primary aldosteronism among patients with apparent treatment-resistant hypertension: Retrospective analysis of current practice. Endocr Pract 2022; 28: 271-275 DOI: 10.1016/j.eprac.2021.11.085.
- 15 Hundemer GL, Kline GA, Leung AA. How common is primary aldosteronism?. Curr Opin Nephrol Hypertens 2021; 30: 353-360 DOI: 10.1097/MNH.0000000000000702.
- 16 Jaffe G, Gray Z, Krishnan G. et al. Screening rates for primary aldosteronism in resistant hypertension: A cohort study. Hypertension 2020; 75: 650-659 DOI: 10.1161/HYPERTENSIONAHA.119.14359.
- 17 Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17
- 18 Conn JW. Evolution of primary aldosteronism as a highly specific clinical entity. J Am Med Assoc 1960; 172: 1650-1653 DOI: 10.1001/jama.1960.63020150008016.
- 19 Conn JW. Plasma renin activity in primary aldosteronism. Importance in differential diagnosis and in research of essential hypertension. JAMA 1964; 190: 222-225
- 20 Conn JW, Rovner DR, Cohen EL. Normal and altered function of the renin-angiotensin-aldosterone system in man: Applications in clinical and research medicine. Ann Intern Med 1965; 63: 266-284 DOI: 10.7326/0003-4819-63-2-266.
- 21 Channick BJ, Adlin EV, Marks AD. Suppressed plasma renin activity in hypertension. Arch Intern Med 1969; 123: 131-140
- 22 Grim CE. Editorial: Low renin "essential’’ hypertension; a variant of classic primary aldosteronism?. Arch Intern Med 1975; 135: 347-350
- 23 Padfield PL, Brown JJ, Lever AF. et al. Is low-renin hypertension a stage in the development of essential hypertension or a diagnostic entity?. Lancet 1975; 1: 548-550 DOI: 10.1016/s0140-6736(75)91559-7.
- 24 Adlin EV. Letter: Plasma-renin and blood-pressure. Lancet 1975; 1: 699 DOI: 10.1016/s0140-6736(75)91814-0.
- 25 Hiramatsu K, Yamada T, Yukimura Y. et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981; 141: 1589-1593
- 26 Vaidya A, Mulatero P, Baudrand R. et al. The expanding spectrum of primary aldosteronism: Implications for diagnosis, pathogenesis, and treatment. Endocr Rev 2018; 39: 1057-1088 DOI: 10.1210/er.2018-00139.
- 27 Monticone S, Burrello J, Tizzani D. et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017; 69: 1811-1820 DOI: 10.1016/j.jacc.2017.01.052.
- 28 Stowasser M, Ahmed AH, Pimenta E. et al. Factors affecting the aldosterone/renin ratio. Horm Metab Res 2012; 44: 170-176 DOI: 10.1055/s-0031-1295460.
- 29 Baudrand R, Guarda FJ, Torrey J. et al. Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism. J Clin Endocrinol Metab 2016; 101: 3989-3996 DOI: 10.1210/jc.2016-1963.
- 30 Ariens J, Horvath AR, Yang J. et al. Performance of the aldosterone-to-renin ratio as a screening test for primary aldosteronism in primary care. Endocrine 2022; 77: 11-20 DOI: 10.1007/s12020-022-03084-x.
- 31 Hung A, Ahmed S, Gupta A. et al. Performance of the aldosterone to renin ratio as a screening test for primary aldosteronism. J Clin Endocrinol Metab 2021; 106: 2423-2435 DOI: 10.1210/clinem/dgab348.
- 32 Ng E, Gwini SM, Libianto R. et al. Aldosterone, renin, and aldosterone-to-renin ratio variability in screening for primary aldosteronism. J Clin Endocrinol Metab 2022; 108: 33-41 DOI: 10.1210/clinem/dgac568.
- 33 Maciel AAW, Freitas TC, Fagundes GFC. et al. Intraindividual variability of serum aldosterone and its implication for primary aldosteronism screening. J Clin Endocrinol Metab 2022; dgac679 DOI: 10.1210/clinem/dgac679.
- 34 Yozamp N, Hundemer GL, Moussa M. et al. Intraindividual variability of aldosterone concentrations in primary aldosteronism: Implications for case detection. Hypertension 2021; 77: 891-899 DOI: 10.1161/HYPERTENSIONAHA.120.16429.
- 35 Markou A, Pappa T, Kaltsas G. et al. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: A very high odds ratio for progression into arterial hypertension. J Clin Endocrinol Metab 2013; 98: 1409-1416 DOI: 10.1210/jc.2012-3353.
- 36 Brown JM, Siddiqui M, Calhoun DA. et al. The unrecognized prevalence of primary aldosteronism: A cross-sectional study. Ann Intern Med 2020; 173: 10-20 DOI: 10.7326/M20-0065.
- 37 Käyser SC, Dekkers T, Groenewoud HJ. et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: A systematic review and meta-regression analysis. J Clin Endocrinol Metab 2016; 101: 2826-2835 DOI: 10.1210/jc.2016-1472.
- 38 Vaidya A, Malchoff CD, Auchus RJ. et al. An individualized approach to the evaluation and management of primary aldosteronism. Endocr Pract 2017; 23: 680-689 DOI: 10.4158/EP161717.RA.
- 39 Mulatero P, Monticone S, Deinum J. et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: A position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens 2020; 38: 1919-1928 DOI: 10.1097/HJH.0000000000002510.
- 40 Naruse M, Katabami T, Shibata H. et al. Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr J 2022; 69: 327-359 DOI: 10.1507/endocrj.EJ21-0508.
- 41 Calhoun DA, Nishizaka MK, Zaman MA. et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896 DOI: 10.1161/01.hyp.0000040261.30455.b6.
- 42 Mosso L, Carvajal C, González A. et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-165 DOI: 10.1161/01.HYP.0000079505.25750.11.
- 43 Rossi GP, Bernini G, Caliumi C. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300 DOI: 10.1016/j.jacc.2006.07.059.
- 44 Douma S, Petidis K, Doumas M. et al. Prevalence of primary hyperaldosteronism in resistant hypertension: A retrospective observational study. Lancet 2008; 371: 1921-1926 DOI: 10.1016/S0140-6736(08)60834-X.
- 45 Galati S-J, Cheesman KC, Springer-Miller R. et al. Prevalence of primary aldosteronism in an urban hypertensive population. Endocr Pract 2016; 22: 1296-1302 DOI: 10.4158/E161332.OR.
- 46 Xu F, Gao Z, Wang G. et al. Prevalence, subtype classification, and outcomes of treatment of primary aldosteronism: A prospective study in China. Endocr Pract 2021; 27: 478-483 DOI: 10.1016/j.eprac.2020.10.007.
- 47 Turcu AF, Nhan W, Grigoryan S. et al. Primary aldosteronism screening rates differ with sex, race, and comorbidities. J Am Heart Assoc 2022; 11: e025952 DOI: 10.1161/JAHA.122.025952.
- 48 Cohen JB, Cohen DL, Herman DS. et al. Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans : A retrospective cohort study. Ann Intern Med 2021; 174: 289-297 DOI: 10.7326/M20-4873.
- 49 Ito Y, Takeda R, Karashima S. et al. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res 2011; 34: 98-102 DOI: 10.1038/hr.2010.166.
- 50 Vasan RS, Evans JC, Larson MG. et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33-41 DOI: 10.1056/NEJMoa033263.
- 51 Hu J, Shen H, Huo P. et al. Heightened cardiovascular risk in hypertension associated with renin-independent aldosteronism versus renin-dependent aldosteronism: A collaborative study. J Am Heart Assoc 2021; 10: e023082 DOI: 10.1161/JAHA.121.023082.
- 52 Brown JM, Robinson-Cohen C, Luque-Fernandez MA. et al. The spectrum of subclinical primary aldosteronism and incident hypertension: A cohort study. Ann Intern Med 2017; 167: 630-641 DOI: 10.7326/M17-0882.
- 53 Burrello J, Monticone S, Losano I. et al. Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit. Hypertension 2020; 75: 1025-1033 DOI: 10.1161/HYPERTENSIONAHA.119.14063.
- 54 Médeau V, Moreau F, Trinquart L. et al. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: A comparison with hypertensive cases. Clin Endocrinol (Oxf) 2008; 69: 20-28 DOI: 10.1111/j.1365-2265.2008.03213.x.
- 55 Tang A, Pasieka J, Kline G. Normotensive hypokalemic primary aldosteronism: How is this possible?. Endocrine Abstracts 2018; 55: P26
- 56 Huang Y-C, Tsai M-H, Fang Y-W. et al. Normotensive hypokalemic primary hyperaldosteronism mimicking clinical features of anorexia nervosa in a young patient. Medicine (Baltimore) 2020; 99: e20826 DOI: 10.1097/MD.0000000000020826.
- 57 Aziz M, Bloomgarden N, Friedman N. Primary aldosteronism presenting as chronic hypokalemia in a normotensive patient. J Endocr Soc 2022; 6: A256-A257 DOI: 10.1210/jendso/bvac150.527.
- 58 Mantero F, Terzolo M, Arnaldi G. et al. A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85: 637-644 DOI: 10.1210/jcem.85.2.6372.
- 59 Bernini G, Moretti A, Argenio G. et al. Primary aldosteronism in normokalemic patients with adrenal incidentalomas. Eur J Endocrinol 2002; 146: 523-529 DOI: 10.1530/eje.0.1460523.
- 60 Kim HY, Kim SG, Lee KW. et al. Clinical study of adrenal incidentaloma in Korea. Korean J Intern Med 2005; 20: 303-309 DOI: 10.3904/kjim.2005.20.4.303.
- 61 Comlekci A, Yener S, Ertilav S. et al. Adrenal incidentaloma, clinical, metabolic, follow-up aspects: Single centre experience. Endocr 2010; 37: 40-46 DOI: 10.1007/s12020-009-9260-5.
- 62 Kim J, Bae KH, Choi YK. et al. Clinical characteristics for 348 patients with adrenal incidentaloma. Endocrinol Metab (Seoul) 2013; 28: 20-25 DOI: 10.3803/EnM.2013.28.1.20.
- 63 Patrova J, Jarocka I, Wahrenberg H. et al. Clinical outcomes in adrenal incidentaloma: Experience from one center. Endocr Pract 2015; 21: 870-877 DOI: 10.4158/EP15618.OR.
- 64 Tabuchi Y, Otsuki M, Kasayama S. et al. Clinical and endocrinological characteristics of adrenal incidentaloma in Osaka region, Japan. Endocr J 2016; 63: 29-35 DOI: 10.1507/endocrj.EJ15-0404.
- 65 Stavropoulos K, Imprialos KP, Katsiki N. et al. Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. J Clin Hypertens (Greenwich) 2018; 20: 942-948 DOI: 10.1111/jch.13291.
- 66 Jing Y, Hu J, Luo R. et al. Prevalence and characteristics of adrenal tumors in an unselected screening population: A cross-sectional study. Ann Intern Med 2022; 175: 1383-1391 DOI: 10.7326/M22-1619.
- 67 Kmieć P, Zalewska E, Kunicka K. et al. Autonomous aldosterone secretion in patients with adrenal incidentaloma. Biomedicines 2022; 10: 3075 DOI: 10.3390/biomedicines10123075.
- 68 Fassnacht M, Arlt W, Bancos I. et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016; 175: G1-G34 DOI: 10.1530/EJE-16-0467.
- 69 Lee J-M, Kim MK, Ko S-H. et al. Clinical guidelines for the management of adrenal incidentaloma. Endocrinol Metab (Seoul) 2017; 32: 200-218 DOI: 10.3803/EnM.2017.32.2.200.
- 70 Whelton PK, Carey RM, Aronow WS. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71: 1269-1324 DOI: 10.1161/HYP.0000000000000066.
- 71 Williams TA, Burrello J, Sechi LA. et al. Computed tomography and adrenal venous sampling in the diagnosis of unilateral primary aldosteronism. Hypertension 2018; 72: 641-649 DOI: 10.1161/HYPERTENSIONAHA.118.11382.
- 72 Sam D, Kline GA, So B. et al. Discordance between imaging and adrenal vein sampling in primary aldosteronism irrespective of interpretation criteria. J Clin Endocrinol Metab 2019; 104: 1900-1906 DOI: 10.1210/jc.2018-02089.
- 73 Wannachalee T, Caoili E, Nanba K. et al. The concordance between imaging and adrenal vein sampling varies with aldosterone-driver somatic mutation. J Clin Endocrinol Metab 2020; 105: e3628-e3637 DOI: 10.1210/clinem/dgaa482.
- 74 Nanba AT, Nanba K, Byrd JB. et al. Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism. Clin Endocrinol (Oxf) 2017; 87: 665-672 DOI: 10.1111/cen.13442.
- 75 Omata K, Satoh F, Morimoto R. et al. Cellular and genetic causes of idiopathic hyperaldosteronism. Hypertension 2018; 72: 874-880 DOI: 10.1161/HYPERTENSIONAHA.118.11086.
- 76 Nishimoto K, Seki T, Hayashi Y. et al. Human adrenocortical remodeling leading to aldosterone-producing cell cluster generation. Int J Endocrinol 2016; 2016: 7834356 DOI: 10.1155/2016/7834356.
- 77 Piaditis GP, Kaltsas GA, Androulakis II. et al. High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas. Clin Endocrinol (Oxf) 2009; 71: 772-778 DOI: 10.1111/j.1365-2265.2009.03551.x.
- 78 Markou A, Kaltsas GA, Papanastasiou L. et al. Enhanced performance of a modified diagnostic test of primary aldosteronism in patients with adrenal adenomas. Eur J Endocrinol 2022; 186: 265-273 DOI: 10.1530/EJE-21-0625.
- 79 Loh HH, Sukor N. Primary aldosteronism and obstructive sleep apnea: What do we know thus far?. Front Endocrinol (Lausanne) 2022; 13: 976979 DOI: 10.3389/fendo.2022.976979.
- 80 Raff H, Roarty TP. Renin, ACTH, and aldosterone during acute hypercapnia and hypoxia in conscious rats. Am J Physiol 1988; 254: R431-R435 DOI: 10.1152/ajpregu.1988.254.3.R431.
- 81 Di Murro A, Petramala L, Cotesta D. et al. Renin-angiotensin-aldosterone system in patients with sleep apnoea: Prevalence of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2010; 11: 165-172 DOI: 10.1177/1470320310366581.
- 82 Dobrowolski P, Kołodziejczyk-Kruk S, Warchoł-Celińska E. et al. Primary aldosteronism is highly prevalent in patients with hypertension and moderate to severe obstructive sleep apnea. J Clin Sleep Med 2021; 17: 629-637 DOI: 10.5664/jcsm.8960.
- 83 Buffolo F, Li Q, Monticone S. et al. Primary aldosteronism and obstructive sleep apnea: A cross-sectional multi-ethnic study. Hypertension 2019; 74: 1532-1540 DOI: 10.1161/HYPERTENSIONAHA.119.13833.
- 84 Kapur VK, Auckley DH, Chowdhuri S. et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med 2017; 13: 479-504 DOI: 10.5664/jcsm.6506.
- 85 Chee MR, Hoo J, Libianto R. et al. Prospective screening for primary aldosteronism in patients with suspected obstructive sleep apnea. Hypertension 2021; 77: 2094-2103 DOI: 10.1161/HYPERTENSIONAHA.120.16902.
- 86 Chomsky-Higgins Menut K, Pearlstein SS, Conroy PC. et al. Screening for primary aldosteronism in the hypertensive obstructive sleep apnea population is cost-saving. Surgery 2022; 171: 96-103 DOI: 10.1016/j.surg.2021.05.052.
- 87 Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: When, who, and how to screen?. Eur Heart J 2014; 35: 1245-1254 DOI: 10.1093/eurheartj/eht534.
- 88 Viera AJ, Neutze DM. Diagnosis of secondary hypertension: An age-based approach. Am Fam Physician 2010; 82: 1471-1478
- 89 Alam S, Kandasamy D, Goyal A. et al. High prevalence and a long delay in the diagnosis of primary aldosteronism among patients with young-onset hypertension. Clin Endocrinol (Oxf) 2021; 94: 895-903 DOI: 10.1111/cen.14409.
- 90 Nguyen V, Tu TM, Mamauag MJB. et al. Primary aldosteronism more prevalent in patients with cardioembolic stroke and atrial fibrillation. Front Endocrinol (Lausanne) 2022; 13: 869980 DOI: 10.3389/fendo.2022.869980.
- 91 Seccia TM, Letizia C, Muiesan ML. et al. Atrial fibrillation as presenting sign of primary aldosteronism: Results of the Prospective Appraisal on the Prevalence of Primary Aldosteronism in Hypertensive (PAPPHY) Study. J Hypertens 2020; 38: 332-339 DOI: 10.1097/HJH.0000000000002250.
- 92 McCarthy J, Yang J, Clissold B. et al. Hypertension management in stroke prevention: Time to consider primary aldosteronism. Stroke 2021; 52: e626-e634 DOI: 10.1161/STROKEAHA.120.033990.
- 93 Miyaji Y, Kawabata Y, Joki H. et al. Primary aldosteronism in patients with acute stroke: Prevalence and diagnosis during initial hospitalization. BMC Neurol 2016; 16: 177 DOI: 10.1186/s12883-016-0701-5.
- 94 Tyfoxylou E, Voulgaris N, Gravvanis C. et al. High prevalence of primary aldosteronism in patients with type 2 diabetes mellitus and hypertension. Biomedicines 2022; 10: 2308 DOI: 10.3390/biomedicines10092308.
- 95 Memon SS, Lila A, Barnabas R. et al. Prevalence of primary aldosteronism in type 2 diabetes mellitus and hypertension: A prospective study from Western India. Clin Endocrinol (Oxf) 2022; 96: 539-548 DOI: 10.1111/cen.14598.
- 96 Manosroi W, Atthakomol P. High body fat percentage is associated with primary aldosteronism: A cross-sectional study. BMC Endocr Disord 2020; 20: 175 DOI: 10.1186/s12902-020-00654-w.
- 97 Rossi GP, Rossi E, Pavan E. et al. Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol (Oxf) 1998; 49: 713-723 DOI: 10.1046/j.1365-2265.1998.00608.x.